欧洲多发性硬化症治疗市场 – 行业趋势和 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

欧洲多发性硬化症治疗市场 – 行业趋势和 2030 年预测

  • Pharmaceutical
  • Upcoming Report
  • Jan 2023
  • Europe
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Europe Multiple Sclerosis Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 6,026.70 Million
Diagram Market Size (Forecast Year)
USD 10,201.16 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>欧洲多发性硬化症治疗市场、疾病类型(复发缓解型多发性硬化症 (RRMS)、继发性进行性多发性硬化症 (SPMS)、原发性进行性多发性硬化症 (PPMS)、严重复发缓解型多发性硬化症 (RES))、治疗(预防疗法、中止疗法/急性加重治疗、对症疗法)、药物类型(品牌药、仿制药)、最终用户(医院和诊所、诊断实验室、其他)– 行业趋势和预测到 2030 年。

欧洲多发性硬化症治疗市场

欧洲多发性硬化症治疗市场分析和规模

多种传染病给全球医疗保健系统带来的负担日益加重,这是主要考虑因素,发展中国家承担了不成比例的负担。根据印度肝胆科学研究所的数据,全球约 3% 的人口感染了丙型肝炎病毒。全球 HCV 感染发病率的增加,尤其是在发达国家和发展中国家,是导致多发性硬化症治疗市场增长的主要因素。

Data Bridge Market Research 分析,多发性硬化症治疗市场预计到 2030 年将达到 102.0116 亿美元,即 2022 年为 60.267 亿美元,预计在 2022 年至 2030 年的预测期内复合年增长率为 6.8%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外,Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

欧洲多发性硬化症治疗市场范围和细分

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021(可定制为 2015 - 2020)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

疾病类型(复发缓解型多发性硬化症 (RRMS)、继发性进展型多发性硬化症 (SPMS)、原发性进展型多发性硬化症 (PPMS)、重度复发缓解型多发性硬化症 (RES))、治疗(预防性治疗、中止治疗/急性加重治疗、对症治疗)、药物类型(品牌药、仿制药)、最终用户(医院、创伤中心、门诊手术中心等)

覆盖国家

德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区

涵盖的市场参与者

AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Biora Therapeutics, Inc (U.S.), Boehringer Ingelheim International Gmbh (Germany), Amgen Inc. (U.S.), Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Novartis AG (Switzerland)., Bayer AG (Germany), Bristol Myers Squibb Company (U.S.), Biogen (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc (U.K.), Abbott (U.S.), Bio-Rad Laboratories Inc. (U.S.), Mylan N.V. (U.S.)

Market Opportunities

  • Increased R&D Activities by Organizations

Market Definition

Multiple sclerosis (MS) is a chronic and inflammatory immune-mediated condition that can cause axonal transection, demyelination, and neurodegeneration of the spinal cord and brain nerve cells. Some of the frequently used therapies include the administration of injectable, oral and infused medicines, antidepressants, physical therapy and muscle relaxants.

Europe Multiple Sclerosis Treatment Market Dynamics

Drivers

  • Rising Awareness About Multiple Sclerosis

There has been a rising awareness about the disease which is helping in boosting the market growth. For instance, the Multiple Sclerosis Foundation and affiliated groups have started National MS Education and Awareness Month, which is observed in March since 2003 to create awareness about the disease. The main aim of this program is to promote an understanding of multiple sclerosis disease and assist the patients in making educated decisions associated with its treatment. Furthermore, the National MS Society created and launched the “MS Kills Connection > < Connection Kills MS” campaign to connect people suffering from MS, people who treat MS patients, and people who run activities to create a world free of multiple sclerosis. Thus, this factor boosts the market growth.

  • Increasing Occurrence of Multiple Sclerosis

There has been growing occurrences of multiple sclerosis in this region. According to the National Multiple Sclerosis Society’s study, an estimated prevalence of the disease was around 309 cases per 100,000 people in 2010, resulting in total of 727,344 multiple sclerosis cases among adults. Europe is considered a high prevalence region for MS. The Multiple Sclerosis Society stated that about 110,000 people were suffering from the condition in the U.K. in 2018. It is also witnessed that MS is more than twice incident in females in this region. The number of new patients diagnosed every year is also increasing, which means that the number rise from 5,000 patients in 2017 to 6,700 in 2018. Therefore, this incidence rate is boosting the demand for the treatment drugs.

Opportunities

  • Increased R&D Activities by Organizations

Numerous drugs are in the research phase for the treatment of multiple sclerosis (MS) and many are undergoing clinical trials. U.S. FDA has approved several drugs for the treatment of MS namely fingolimod, interferons, natalizumab, glatiramer acetate, teriflunomide, and dimethyl fumarate. Several geneticists as well as other researchers are studying human genome for causes and other possible treatments for diseases such as muscular dystrophy, Alzheimer's, cancer and diabetes. For instance, they have found that some people with a specific gene are more likely to develop Alzheimer's disease. So researchers are now working on drugs that will modify or repair that particular gene. Likewise, many researchers have found that some people suffering from multiple sclerosis have a certain gene which makes them more vulnerable to the disease. Hence, they are now consistently working on drugs that will either alter or repair that gene.

Restraints/Challenges

  • High cost of Drugs

The cost of multiple sclerosis drugs remains a constant challenge to the market growth despite of the high prevalence of multiple sclerosis. The high pricing of drugs makes it inefficient to meet the needs pf the affected population. DMTs are the standard option for treatment but the extreme cost of these drugs leads to the improper adherence and disease management. As per the National Multiple Sclerois Society, the cost of MS drugs are increasing hugely. This factor is anticipated to limit the market growth.

This multiple sclerosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multiple sclerosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

  • In 2021, Janssen received U.S. FDA approval for Ponvory. It is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, that is used to treat adults with relapsing forms of multiple sclerosis (MS), such as clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
  • In 2020, Novartis announced that the US FDA approval for Kesimpta in the form of an injection for subcutaneous use for treating the relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Europe Multiple Sclerosis Treatment Market Scope

多发性硬化症治疗市场根据疾病类型、治疗、药物类型和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

疾病类型

  • 复发缓解型多发性硬化症 (RRMS)
  • 继发性进行性多发性硬化症 (SPMS)
  • 原发性进行性多发性硬化症 (PPMS)
  • 严重复发缓解型多发性硬化症 (RES)

治疗

  • 预防疗法
  • 急性加重的终止疗法/治疗
  • 对症治疗

药物类型

  • 品牌
  • 通用的

给药途径

  • 口服
  • 肠外

终端用户

  • 医院和诊所
  • 诊断实验室
  • 其他的

多发性硬化症治疗区域分析/见解

对多发性硬化症治疗市场进行了分析,并根据上述疾病类型、治疗、药物类型和最终用户提供了市场规模洞察和趋势。

多发性硬化症治疗市场报告涉及的国家包括欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其和欧洲其他地区。

由于德国引入了全新的多发性硬化症治疗方案,预计在 2023 年至 2030 年的预测期内,德国将引领市场。该地区药物研发的不断增长也推动了市场的增长。人们对多发性硬化症及其治疗的认识不断提高,有助于引领市场增长。  

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和欧洲多发性硬化症治疗市场份额分析

多发性硬化症治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对多发性硬化症治疗市场的关注有关。

多发性硬化症治疗市场的一些主要参与者包括:

  • AbbVie Inc.(美国)
  • Bausch Health Companies Inc.(加拿大)
  • Biora Therapeutics, Inc(美国)
  • 勃林格殷格翰国际有限公司 (德国)
  • 安进公司 (美国)
  • 辉瑞公司 (美国)
  • F. Hoffmann-La Roche Ltd(瑞士)
  • Mylan NV(美国)
  • 诺华公司(瑞士)
  • 拜耳公司(德国)
  • 百时美施贵宝公司 (美国)
  • Biogen(美国)
  • 梯瓦制药工业有限公司 (以色列)
  • 武田药品工业株式会社 (日本)
  • Jazz Pharmaceuticals, Inc(英国)
  • 雅培(美国)
  • Bio-Rad Laboratories Inc.(美国)
  • Mylan NV(美国)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Europe Multiple Sclerosis Treatment Market will be worth USD 10,201.16 million by 2030 during the forecast period.
The Europe Multiple Sclerosis Treatment Market growth rate is 6.8% during the forecast period.
Rising Awareness About Multiple Sclerosis & Increasing Occurrence of Multiple Sclerosis are the growth drivers of the Europe Multiple Sclerosis Treatment Market.
The disease type, treatment, drug type, and end-user are the factors on which the Europe Multiple Sclerosis Treatment Market research is based.
Major companies in the Europe Multiple Sclerosis Treatment Market are AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Biora Therapeutics, Inc (U.S.), Boehringer Ingelheim International Gmbh (Germany), Amgen Inc. (U.S.), Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Novartis AG (Switzerland)., Bayer AG (Germany), Bristol Myers Squibb Company (U.S.), Biogen (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc (U.K.), Abbott (U.S.), Bio-Rad Laboratories Inc. (U.S.), Mylan N.V. (U.S.)